Kristine Zengeler, The Conversation | Dec 8, 2022 | 5 min read
Dialing up the activity of a protein called SYK in the brain’s “janitors” could provide an avenue to treat Alzheimer’s and other neurodegenerative diseases.
The APOE4 variant causes cholesterol buildup in the cells that make protective fatty sheaths for neurons, possibly helping explain its role in neurodegeneration.
Damaged lysosomes are repaired by a lipid-based signaling pathway dubbed PITT that could be targeted to treat neurodegenerative disease, its discoverers say.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
Mice with overactive LINE-1 retrotransposons in their brains exhibit movement difficulties, suggesting the genetic elements may play a role in ataxia in humans.
Research traces the evolution of a gene variant that reduces the risk of Alzheimer’s disease, finding that it originally evolved in response to infectious bacteria.